guaifenesin has been researched along with Hyperplasia in 87 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both mucus discharge and induction of goblet cell hyperplasia reduce radiation burden at the cellular level, and as such they both can be considered as radioadaptive responses to radon exposure." | 7.88 | Effects of mucus thickness and goblet cell hyperplasia on microdosimetric quantities characterizing the bronchial epithelium upon radon exposure. ( Drozsdik, EJ; Madas, BG, 2018) |
| "Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation." | 7.81 | Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. ( Ding, PS; Fang, L; He, F; Liu, RY; Shen, QY; Wu, HM, 2015) |
| "We have reported that triptolide inhibited pulmonary inflammation in patients with steroid-resistant asthma." | 7.81 | Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. ( Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015) |
| "Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 7.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
| "The effects of niflumic acid (NA), a relatively specific blocker of calcium-activated chloride channel (CLCA), on goblet cell hyperplasia, eosinophil accumulation, and airway hyperresponsiveness were evaluated after IL-13 instillation into the airways." | 7.73 | Niflumic acid suppresses interleukin-13-induced asthma phenotypes. ( Aizawa, H; Fukuyama, S; Inoue, H; Matsumoto, K; Matsumoto, T; Matsumura, M; Nakanishi, Y; Nakano, T; Tsuda, M, 2006) |
| "The present investigation explores whether N-acetylcysteine (NAC) inhibits the secretory cell hyperplasia known to occur experimentally in specific pathogen-free (SPF) bronchitic rats." | 7.67 | Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. ( Ayers, MM; Jeffery, PK; Rogers, DF, 1985) |
| "Compared with IL 33 group, the inflammatory cell infiltration around the trachea and blood vessels of the lung tissue in the IL 33+ Iloprost group were reduced; goblet cell hyperplasia was observed in airway mucosa of IL 33 group, and the mucus secretion increased; the percentage of EOS and ILC2s in the BALF and lung single cell suspensions in IL 33+ Iloprost group were statistically lower than that of IL 33 group (p < 0." | 3.96 | Iloprost inhibits acute allergic nasal inflammation by GATA3 -ILC2 pathway in mice. ( Jiang, X; Li, L; Liu, H; Liu, J; Liu, K; Yang, C; Zhang, X, 2020) |
| "Both mucus discharge and induction of goblet cell hyperplasia reduce radiation burden at the cellular level, and as such they both can be considered as radioadaptive responses to radon exposure." | 3.88 | Effects of mucus thickness and goblet cell hyperplasia on microdosimetric quantities characterizing the bronchial epithelium upon radon exposure. ( Drozsdik, EJ; Madas, BG, 2018) |
| "Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation." | 3.81 | Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. ( Ding, PS; Fang, L; He, F; Liu, RY; Shen, QY; Wu, HM, 2015) |
| "We have reported that triptolide inhibited pulmonary inflammation in patients with steroid-resistant asthma." | 3.81 | Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. ( Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015) |
| " Oral administration of ≥10 mg/kg kaempferol suppressed mucus secretion and goblet cell hyperplasia observed in the bronchial airway and lung of BALB/c mice sensitized with ovalbumin (OVA)." | 3.81 | Kaempferol Inhibits Endoplasmic Reticulum Stress-Associated Mucus Hypersecretion in Airway Epithelial Cells And Ovalbumin-Sensitized Mice. ( Choi, YJ; Gong, JH; Kang, MK; Kang, YH; Kim, YH; Park, SH, 2015) |
| "Hydrogen-rich saline pretreatment attenuated CS-induced mucus accumulation in the bronchiolar lumen, goblet cell hyperplasia, muc5ac over-expression and abnormal cell apoptosis in the airway epithelium as well as malondialdehyde increase in the BALF." | 3.79 | Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats. ( Dong, Y; Huang, H; Li, Q; Ning, Y; Shang, Y; Xu, W; Zhang, J, 2013) |
| "Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." | 3.78 | Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012) |
| "Nicotine-induced airway mucus formation is independent of IL-13, and α7-nAChRs are critical in airway mucous cell metaplasia/hyperplasia and mucus production in response to various promucoid agents, including IL-13." | 3.78 | Role of nicotinic receptors and acetylcholine in mucous cell metaplasia, hyperplasia, and airway mucus formation in vitro and in vivo. ( Buch, S; Gott, KM; Gundavarapu, S; Harrod, KS; Jaramillo, RJ; Langley, RJ; McIntosh, JM; Mishra, NC; Peña-Philippides, JC; Rir-Sima-Ah, J; Saeed, AI; Singh, SP; Sopori, ML; Wilder, JA, 2012) |
| "The effects of niflumic acid (NA), a relatively specific blocker of calcium-activated chloride channel (CLCA), on goblet cell hyperplasia, eosinophil accumulation, and airway hyperresponsiveness were evaluated after IL-13 instillation into the airways." | 3.73 | Niflumic acid suppresses interleukin-13-induced asthma phenotypes. ( Aizawa, H; Fukuyama, S; Inoue, H; Matsumoto, K; Matsumoto, T; Matsumura, M; Nakanishi, Y; Nakano, T; Tsuda, M, 2006) |
| "The present investigation explores whether N-acetylcysteine (NAC) inhibits the secretory cell hyperplasia known to occur experimentally in specific pathogen-free (SPF) bronchitic rats." | 3.67 | Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. ( Ayers, MM; Jeffery, PK; Rogers, DF, 1985) |
| "Characteristic pathologic changes in chronic obstructive pulmonary disease (COPD) include an increased fractional volume of bronchiolar epithelial cells, fibrous thickening of the airway wall, and luminal inflammatory mucus exudates, which are positively correlated with airflow limitation and disease severity." | 2.43 | Airway epithelial stem cells and the pathophysiology of chronic obstructive pulmonary disease. ( Randell, SH, 2006) |
| "In 12 cases foreign bodies (fish bones) were found fixed in calculi." | 1.39 | Sialendoscopic findings in patients with obstructive sialadenitis: long-term experience. ( Chi, Y; Chuangqi, Y; Lingyan, Z, 2013) |
| "The preoperative diagnosis was type III hydatid cyst of the psoas, psoas tumor or retroperitoneal mass." | 1.30 | [Appendiceal mucocele disclosed by a psoas tumor. Apropos of a case]. ( Benjelloun, S; Debbagh, A; el Moussaoui, A; Hafiani, M; Rabii, R; Rais, H, 1998) |
| " There were no significant differences in age, sex, smoking history, duration of BA history, and dosage of glucocorticoids received between groups A and B." | 1.28 | Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. ( Aikawa, T; Ebina, M; Sasaki, H; Shimura, S; Takishima, T, 1992) |
| "Similarly in some gastric cancers which do not stain with the periodic acid-Schiff reaction at all, large amount of free or neuraminic acid substituted PNA binding sites can be detected." | 1.27 | Characterization of glycoconjugates of human gastrointestinal mucosa by lectins. I. Histochemical distribution of lectin binding sites in normal alimentary tract as well as in benign and malignant gastric neoplasms. ( Fischer, J; Fischer, R; Klein, PJ; Skutta, B; Uhlenbruck, G; Vierbuchen, M, 1984) |
| "Ductal hyperplasia was divided into 3 types; nonpapillary, papillary, and atypical hyperplasia." | 1.26 | Relation of pancreatic duct hyperplasia to carcinoma. ( Hasegawa, K; Kozuka, S; Masamoto, K; Nagasawa, S; Saga, S; Sassa, R; Takeuchi, M; Taki, T, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (18.39) | 18.7374 |
| 1990's | 14 (16.09) | 18.2507 |
| 2000's | 26 (29.89) | 29.6817 |
| 2010's | 26 (29.89) | 24.3611 |
| 2020's | 5 (5.75) | 2.80 |
| Authors | Studies |
|---|---|
| Friedman, WH | 1 |
| Katsantonis, GP | 1 |
| Bumpous, JM | 1 |
| Li, D | 1 |
| Luan, N | 1 |
| Li, J | 1 |
| Zhao, H | 2 |
| Zhang, Y | 2 |
| Long, R | 1 |
| Jiang, G | 1 |
| Fan, S | 1 |
| Xu, X | 1 |
| Cao, H | 1 |
| Wang, Y | 2 |
| Liao, Y | 1 |
| Wang, L | 1 |
| Liu, L | 1 |
| Liu, C | 1 |
| Li, Q | 2 |
| Lu, X | 1 |
| Tan, ZX | 1 |
| Wang, WJ | 1 |
| Zhan, P | 1 |
| Fu, L | 1 |
| Gao, L | 1 |
| Wang, H | 1 |
| Xu, DX | 1 |
| Campbell, L | 1 |
| Hepworth, MR | 1 |
| Whittingham-Dowd, J | 1 |
| Thompson, S | 1 |
| Bancroft, AJ | 1 |
| Hayes, KS | 1 |
| Shaw, TN | 1 |
| Dickey, BF | 1 |
| Flamar, AL | 1 |
| Artis, D | 1 |
| Schwartz, DA | 1 |
| Evans, CM | 1 |
| Roberts, IS | 1 |
| Thornton, DJ | 1 |
| Grencis, RK | 1 |
| Liu, J | 1 |
| Jiang, X | 1 |
| Li, L | 1 |
| Liu, H | 1 |
| Zhang, X | 3 |
| Liu, K | 1 |
| Yang, C | 1 |
| Zimmer, V | 1 |
| Kreissler-Haag, D | 1 |
| Hübschen, U | 1 |
| Mues, EP | 1 |
| Chen, R | 1 |
| Liang, Y | 1 |
| Ip, MSM | 1 |
| Zhang, KY | 1 |
| Mak, JCW | 1 |
| Hussain, SS | 1 |
| George, S | 1 |
| Singh, S | 1 |
| Jayant, R | 1 |
| Hu, CA | 1 |
| Sopori, M | 1 |
| Chand, HS | 1 |
| Madas, BG | 1 |
| Drozsdik, EJ | 1 |
| Barrios, J | 1 |
| Kho, AT | 1 |
| Aven, L | 1 |
| Mitchel, JA | 1 |
| Park, JA | 1 |
| Randell, SH | 2 |
| Miller, LA | 1 |
| Tantisira, KG | 1 |
| Ai, X | 1 |
| Ning, Y | 1 |
| Shang, Y | 1 |
| Huang, H | 1 |
| Zhang, J | 1 |
| Dong, Y | 1 |
| Xu, W | 1 |
| Chen, Y | 2 |
| Wu, H | 1 |
| Nie, YC | 1 |
| Li, PB | 1 |
| Shen, JG | 1 |
| Su, WW | 1 |
| Shen, QY | 1 |
| Fang, L | 1 |
| Wu, HM | 1 |
| He, F | 1 |
| Ding, PS | 1 |
| Liu, RY | 1 |
| Chen, M | 1 |
| Lv, Z | 1 |
| Zhang, W | 2 |
| Huang, L | 1 |
| Lin, X | 1 |
| Shi, J | 1 |
| Liang, R | 1 |
| Jiang, S | 1 |
| Balázs, A | 1 |
| Hegyi, P | 1 |
| Park, SH | 1 |
| Gong, JH | 1 |
| Choi, YJ | 1 |
| Kang, MK | 1 |
| Kim, YH | 1 |
| Kang, YH | 1 |
| Chen, H | 1 |
| Xia, Q | 1 |
| Feng, X | 1 |
| Cao, F | 1 |
| Yu, H | 1 |
| Song, Y | 1 |
| Ni, X | 1 |
| Hoffman, SM | 1 |
| Qian, X | 1 |
| Nolin, JD | 1 |
| Chapman, DG | 1 |
| Chia, SB | 1 |
| Lahue, KG | 1 |
| Schneider, R | 1 |
| Ather, JL | 1 |
| Randall, MJ | 1 |
| McMillan, DH | 1 |
| Jones, JT | 1 |
| Taatjes, DJ | 1 |
| Aliyeva, M | 1 |
| Daphtary, N | 1 |
| Abdalla, S | 1 |
| Lundblad, LK | 1 |
| Ho, YS | 1 |
| Anathy, V | 1 |
| Irvin, CG | 1 |
| Wouters, EF | 1 |
| Reynaert, NL | 1 |
| Dixon, AE | 1 |
| van der Vliet, A | 1 |
| Poynter, ME | 1 |
| Janssen-Heininger, YM | 1 |
| Widmer, A | 1 |
| Doherr, MG | 1 |
| Tessier, C | 1 |
| Koch, C | 1 |
| Ramseyer, A | 1 |
| Straub, R | 1 |
| Gerber, V | 1 |
| Siddiqui, S | 1 |
| Martin, JG | 1 |
| Guk, SM | 1 |
| Lee, JH | 1 |
| Kim, HJ | 1 |
| Kim, WH | 1 |
| Shin, EH | 1 |
| Chai, JY | 1 |
| Lai, HY | 1 |
| Rogers, DF | 5 |
| Jung, ME | 1 |
| Cho, GM | 1 |
| Byun, SW | 1 |
| Do, KR | 1 |
| Kim, HK | 1 |
| Cho, YS | 1 |
| Chae, HS | 1 |
| Shin, OR | 1 |
| Kim, SS | 1 |
| Nishimoto, Y | 1 |
| Hisatsune, A | 1 |
| Katsuki, H | 1 |
| Miyata, T | 1 |
| Yokomizo, K | 1 |
| Isohama, Y | 1 |
| Lukacs, NW | 1 |
| Smit, JJ | 1 |
| Mukherjee, S | 1 |
| Morris, SB | 1 |
| Nunez, G | 1 |
| Lindell, DM | 1 |
| Lai, H | 1 |
| Horst, D | 1 |
| Gu, X | 1 |
| Bhasin, M | 1 |
| Yang, Q | 1 |
| Verzi, M | 1 |
| Lin, D | 1 |
| Joseph, M | 1 |
| Chen, W | 1 |
| Li, YP | 1 |
| Shivdasani, RA | 1 |
| Libermann, TA | 1 |
| Mebratu, YA | 1 |
| Schwalm, K | 1 |
| Smith, KR | 1 |
| Schuyler, M | 1 |
| Tesfaigzi, Y | 2 |
| Tanabe, T | 2 |
| Kanoh, S | 1 |
| Tsushima, K | 2 |
| Yamazaki, Y | 1 |
| Kubo, K | 1 |
| Rubin, BK | 1 |
| Hao, Y | 1 |
| Kuang, Z | 1 |
| Walling, BE | 1 |
| Bhatia, S | 1 |
| Sivaguru, M | 1 |
| Gaskins, HR | 1 |
| Lau, GW | 1 |
| Khakzad, MR | 1 |
| Mirsadraee, M | 1 |
| Mohammadpour, A | 1 |
| Ghafarzadegan, K | 1 |
| Hadi, R | 1 |
| Saghari, M | 1 |
| Meshkat, M | 1 |
| Villenave, R | 1 |
| Thavagnanam, S | 1 |
| Sarlang, S | 1 |
| Parker, J | 1 |
| Douglas, I | 1 |
| Skibinski, G | 1 |
| Heaney, LG | 1 |
| McKaigue, JP | 1 |
| Coyle, PV | 1 |
| Shields, MD | 1 |
| Power, UF | 1 |
| Gundavarapu, S | 1 |
| Wilder, JA | 1 |
| Mishra, NC | 1 |
| Rir-Sima-Ah, J | 1 |
| Langley, RJ | 1 |
| Singh, SP | 1 |
| Saeed, AI | 1 |
| Jaramillo, RJ | 1 |
| Gott, KM | 1 |
| Peña-Philippides, JC | 1 |
| Harrod, KS | 1 |
| McIntosh, JM | 1 |
| Buch, S | 1 |
| Sopori, ML | 1 |
| Tao, B | 1 |
| Wang, D | 1 |
| Cheng, H | 1 |
| Wang, K | 1 |
| Zhou, R | 1 |
| Xie, Q | 1 |
| Ke, Y | 1 |
| Chuangqi, Y | 1 |
| Chi, Y | 1 |
| Lingyan, Z | 1 |
| Kibe, A | 1 |
| Inoue, H | 2 |
| Fukuyama, S | 2 |
| Machida, K | 1 |
| Matsumoto, K | 2 |
| Koto, H | 1 |
| Ikegami, T | 1 |
| Aizawa, H | 2 |
| Hara, N | 1 |
| Harkema, JR | 2 |
| Wagner, JG | 1 |
| Vermeer, PD | 1 |
| Harson, R | 1 |
| Einwalter, LA | 1 |
| Moninger, T | 1 |
| Zabner, J | 1 |
| Lee, HM | 1 |
| Choi, JH | 1 |
| Chae, SW | 1 |
| Hwang, SJ | 1 |
| Lee, SH | 1 |
| Ogawa, T | 1 |
| Maeda, K | 1 |
| Tonai, S | 1 |
| Kobayashi, T | 1 |
| Watanabe, T | 1 |
| Okabe, S | 1 |
| Kelly-Welch, AE | 1 |
| Melo, ME | 1 |
| Smith, E | 1 |
| Ford, AQ | 1 |
| Haudenschild, C | 1 |
| Noben-Trauth, N | 1 |
| Keegan, AD | 1 |
| Yoshisue, H | 1 |
| Hasegawa, K | 2 |
| Bernstein, JM | 1 |
| Kansal, R | 1 |
| Inglis, SK | 1 |
| Wilson, SM | 1 |
| Nakano, T | 1 |
| Matsumura, M | 1 |
| Tsuda, M | 1 |
| Matsumoto, T | 1 |
| Nakanishi, Y | 1 |
| Long, AJ | 1 |
| Sypek, JP | 1 |
| Askew, R | 1 |
| Fish, SC | 1 |
| Mason, LE | 1 |
| Williams, CM | 1 |
| Goldman, SJ | 1 |
| Muz, MH | 1 |
| Deveci, F | 1 |
| Bulut, Y | 1 |
| Ilhan, N | 1 |
| Yekeler, H | 1 |
| Turgut, T | 1 |
| Holcombe, SJ | 1 |
| Robinson, NE | 1 |
| Derksen, FJ | 1 |
| Bertold, B | 1 |
| Genovese, R | 1 |
| Miller, R | 1 |
| de Feiter Rupp, H | 1 |
| Carr, EA | 1 |
| Eberhart, SW | 1 |
| Boruta, D | 1 |
| Kaneene, JB | 1 |
| Chapman, RW | 1 |
| Minnicozzi, M | 1 |
| Celly, CS | 1 |
| Phillips, JE | 1 |
| Kung, TT | 1 |
| Hipkin, RW | 1 |
| Fan, X | 1 |
| Rindgen, D | 1 |
| Deno, G | 1 |
| Bond, R | 1 |
| Gonsiorek, W | 1 |
| Billah, MM | 1 |
| Fine, JS | 1 |
| Hey, JA | 1 |
| Fujimoto, K | 1 |
| Yasuo, M | 1 |
| Yoshida, K | 1 |
| Ise, H | 1 |
| Yamaya, M | 1 |
| Fischer, J | 1 |
| Klein, PJ | 1 |
| Vierbuchen, M | 1 |
| Skutta, B | 1 |
| Uhlenbruck, G | 1 |
| Fischer, R | 1 |
| Rikihisa, Y | 1 |
| Lin, YC | 1 |
| Jeffery, PK | 2 |
| Ayers, M | 1 |
| Rogers, D | 1 |
| Douglas, AN | 1 |
| Pon, DJ | 1 |
| van Staden, CJ | 1 |
| Boulet, L | 1 |
| Rodger, IW | 1 |
| Gordon, T | 1 |
| Andoh, Y | 1 |
| Shimura, S | 2 |
| Sawai, T | 1 |
| Sasaki, H | 2 |
| Takishima, T | 2 |
| Shirato, K | 1 |
| Ohta, T | 1 |
| Nagakawa, T | 1 |
| Yoshimitsu, Y | 1 |
| Sanada, H | 1 |
| Fonseca, L | 1 |
| Miyazaki, I | 1 |
| Terada, T | 1 |
| Shimizu, T | 1 |
| Takahashi, Y | 1 |
| Kawaguchi, S | 1 |
| Sakakura, Y | 1 |
| Kellokumpu, IH | 1 |
| Andersson, LC | 1 |
| Kellokumpu, SJ | 1 |
| el Moussaoui, A | 1 |
| Rabii, R | 1 |
| Hafiani, M | 1 |
| Rais, H | 1 |
| Debbagh, A | 1 |
| Benjelloun, S | 1 |
| Fischer, MJ | 1 |
| Martin, AJ | 1 |
| Seagrave, J | 1 |
| Shimoyama, T | 1 |
| Wakabayashi, M | 1 |
| Kato, T | 1 |
| Kaneko, T | 1 |
| Horie, N | 1 |
| Ide, F | 1 |
| Rose, MC | 1 |
| Nickola, TJ | 1 |
| Voynow, JA | 1 |
| Fahy, JV | 1 |
| Maestrelli, P | 1 |
| Saetta, M | 1 |
| Mapp, CE | 1 |
| Fabbri, LM | 1 |
| McMillan, SJ | 1 |
| Bishop, B | 1 |
| Townsend, MJ | 1 |
| McKenzie, AN | 1 |
| Lloyd, CM | 1 |
| Kozuka, S | 1 |
| Sassa, R | 1 |
| Taki, T | 1 |
| Masamoto, K | 1 |
| Nagasawa, S | 1 |
| Saga, S | 1 |
| Takeuchi, M | 1 |
| Filipe, MI | 1 |
| Aikawa, T | 1 |
| Ebina, M | 1 |
| Cohen, PR | 1 |
| Tos, M | 1 |
| Larsen, PL | 1 |
| Møller, K | 1 |
| Spurzem, JR | 1 |
| Thompson, AB | 1 |
| Daughton, DM | 1 |
| Mueller, M | 1 |
| Linder, J | 1 |
| Rennard, SI | 1 |
| Harrison, DF | 1 |
| Ayers, MM | 1 |
| Althoff, J | 1 |
| Cardesa, A | 1 |
| Pour, P | 1 |
| Mohr, U | 1 |
| Mawdesley-Thomas, LE | 1 |
| Healey, P | 1 |
| Kilburn, KH | 1 |
| Servin, A | 1 |
| Garcet, S | 1 |
| Quevauviller, A | 1 |
| Chakrin, LW | 1 |
| Saunders, LZ | 1 |
| Weir, TW | 1 |
| Johnson, WC | 1 |
| Ely, JW | 1 |
| Hall, RC | 1 |
| Tepperman, J | 1 |
| Lev, R | 1 |
| Siegel, HI | 1 |
| Glass, GB | 1 |
| Macgregor, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis (HYBRID): A Randomized, Multi-center, Double-blind, Parallel-group Study[NCT02765295] | 120 participants (Anticipated) | Interventional | 2016-06-01 | Recruiting | |||
| Adjuvant Therapy for Severe COPD Patients in the Stable Phase by an Oxyhydrogen Generator With Nebulizer: A Multi-centric, Randomized, Parallel-control and Double-blinded Clinic Study[NCT02850185] | 170 participants (Anticipated) | Interventional | 2016-07-15 | Recruiting | |||
| Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer: A Multi-centric, Randomized, Parallel-control and Double-blinded Clinic Study on Effectiveness and Safety[NCT02883582] | 150 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | |||
| Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190] | Phase 1 | 6 participants (Actual) | Interventional | 2017-06-05 | Terminated (stopped due to Phase II funding not available) | ||
| Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608] | 29 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Evidence that the dose is insufficient.) | |||
| Clinical Evaluation of Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for Symptomatic Relief of Chronic Rhinitis[NCT03727347] | 50 participants (Actual) | Interventional | 2018-10-16 | Completed | |||
| "Validation of a Questionnaire to Assess Bronchial Mucus Hypersecretion in Asthmatic Patients. Questionnaire T-sec (Secretion Test)."[NCT05546645] | 100 participants (Anticipated) | Observational | 2023-10-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase Ib | 0 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
| Intervention | mmHg (Mean) |
|---|---|
| Treatment | -0.6 |
| Control | 1 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.
| Intervention | beats per minute (Mean) |
|---|---|
| Treatment | -1.4 |
| Control | 4 |
Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -1.3 |
| Control | -0.25 |
Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Treatment | 12.5 |
| Control | 17.7 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -44.03 |
| Control | -6.07 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment | -27.3 |
| Control | 0.4 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
| Intervention | mmHg (Mean) |
|---|---|
| Treatment | -4.5 |
| Control | -6.6 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
| Open Label | 64.3 | 35.0 | 90.0 | 16.7 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
| Open Label | 31.8 | 24.14 | 72.00 | 8.00 |
"Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value.~The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit" (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure
| Intervention | units on a scale (Mean) |
|---|---|
| InSeca Stylus Treatment Group | -5.1 |
"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity.~The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded." (NCT03727347)
Timeframe: Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Group - Baseline | 8.5 |
| Treatment Group - 2 Week Data | 4.8 |
| Treatment Group - 4 Week Data | 3.6 |
| Treatment Group - 12 Week Data | 3.4 |
| Treatment Group - 26 Week Data | 3.3 |
| Treatment Group - 52 Week Data | 3.6 |
"Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure.~This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure." (NCT03727347)
Timeframe: At or following the study procedure, and up to the final study visit at 1 year.
| Intervention | Participants (Count of Participants) |
|---|---|
| InSeca Stylus Treatment Group | 8 |
"The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected." (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| InSeca Stylus Treatment Group | 46 |
"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity." (NCT03727347)
Timeframe: Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Rhinorrhea | Nasal Congestion | Nasal Itching | Sneezing | |
| Treatment Group - 12 Week Data | 1.0 | 1.1 | 0.5 | 0.9 |
| Treatment Group - 2 Week Data | 1.6 | 1.5 | 0.7 | 1.0 |
| Treatment Group - 26 Week Data | 0.9 | 1.1 | 0.5 | 0.8 |
| Treatment Group - 4 Week Data | 1.2 | 1.1 | 0.4 | 0.8 |
| Treatment Group - 52 Week Data | 1.1 | 1.2 | 0.5 | 0.8 |
| Treatment Group - Baseline | 2.5 | 2.5 | 1.7 | 1.9 |
"This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative.~Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response." (NCT03727347)
Timeframe: The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Section 1, Item 1: Difficulty falling asleep72500892 | Section 1, Item 1: Difficulty falling asleep72500885 | Section 1, Item 1: Difficulty falling asleep72500891 | Section 1, Item 1: Difficulty falling asleep72500893 | Section 1, Item 2: Good sleep throughout the night72500885 | Section 1, Item 2: Good sleep throughout the night72500891 | Section 1, Item 2: Good sleep throughout the night72500892 | Section 1, Item 2: Good sleep throughout the night72500893 | Section 1, Item 3: Feeling fatigued during the day72500885 | Section 1, Item 3: Feeling fatigued during the day72500891 | Section 1, Item 3: Feeling fatigued during the day72500892 | Section 1, Item 3: Feeling fatigued during the day72500893 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500885 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500891 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500892 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500893 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500885 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500891 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500892 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500893 | Section 1, Item 6: Having a good sense of overall well-being72500885 | Section 1, Item 6: Having a good sense of overall well-being72500891 | Section 1, Item 6: Having a good sense of overall well-being72500892 | Section 1, Item 6: Having a good sense of overall well-being72500893 | Section 2, Item 1: Oral medications72500885 | Section 2, Item 1: Oral medications72500891 | Section 2, Item 1: Oral medications72500892 | Section 2, Item 1: Oral medications72500893 | Section 2, Item 2: Nasal sprays72500885 | Section 2, Item 2: Nasal sprays72500891 | Section 2, Item 2: Nasal sprays72500892 | Section 2, Item 2: Nasal sprays72500893 | Section 2, Item 3: Nasal breathing strips72500885 | Section 2, Item 3: Nasal breathing strips72500891 | Section 2, Item 3: Nasal breathing strips72500892 | Section 2, Item 3: Nasal breathing strips72500893 | |||||||||||||||||||||||||||||||||||||
| Positive (favorable) response | Neutral or Negative response | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 41 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
14 reviews available for guaifenesin and Hyperplasia
| Article | Year |
|---|---|
Cystic fibrosis-style changes in the early phase of pancreatitis.
Topics: Acidosis; Alcoholism; Bicarbonates; Body Water; Cystic Fibrosis Transmembrane Conductance Regulator; | 2015 |
Structural aspects of airway remodeling in asthma.
Topics: Animals; Asthma; Cell Proliferation; Cytokines; Epithelial Cells; Extracellular Matrix Proteins; Fib | 2008 |
Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.
Topics: Animals; Asthma; Drug Delivery Systems; Drug Therapy; ErbB Receptors; Goblet Cells; Humans; Hyperpla | 2010 |
New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.
Topics: Animals; Asthma; Cyclooxygenase 2; Cytokines; Drug Delivery Systems; Goblet Cells; Humans; Hyperplas | 2010 |
Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory?
Topics: Animals; Asthma; Goblet Cells; Guinea Pigs; Humans; Hyperplasia; Interleukins; Mice; Models, Animal; | 2002 |
Non-allergic models of mucous cell metaplasia and mucus hypersecretion in rat nasal and pulmonary airways.
Topics: Animals; Drosophila Proteins; Endotoxins; Epithelial Cells; ErbB Receptors; Exocrine Glands; Exocyto | 2002 |
Cystic fibrosis and airway submucosal glands.
Topics: Cystic Fibrosis; Exocrine Glands; Humans; Hyperplasia; Lung; Mucus | 2005 |
Airway epithelial stem cells and the pathophysiology of chronic obstructive pulmonary disease.
Topics: Bronchi; Cell Differentiation; Cell Proliferation; Humans; Hyperplasia; Metaplasia; Mucus; Pulmonary | 2006 |
The mechanisms and control of bronchial mucous cell hyperplasia.
Topics: Animals; Anti-Inflammatory Agents; Bronchi; Cell Differentiation; Cell Division; Epithelium; Humans; | 1982 |
Airway goblet cells: responsive and adaptable front-line defenders.
Topics: Animals; Asthma; Bronchitis; Cystic Fibrosis; Exocrine Glands; Humans; Hyperplasia; Mucins; Mucus; P | 1994 |
Airway mucus obstruction: mucin glycoproteins, MUC gene regulation and goblet cell hyperplasia.
Topics: Airway Obstruction; Gene Expression Regulation; Glycoproteins; Goblet Cells; Humans; Hyperplasia; Mu | 2001 |
Remodeling of the airway epithelium in asthma.
Topics: Animals; Asthma; Biopsy; Bronchi; Bronchoconstriction; Capillary Permeability; Cell Degranulation; C | 2001 |
Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease.
Topics: Biopsy; Bronchitis; CD4-CD8 Ratio; Chronic Disease; Goblet Cells; Humans; Hyperplasia; Inflammation; | 2001 |
Biological effects of cigarette smoking in the pathogenesis of pulmonary disease.
Topics: Animals; Bacteriolysis; Bronchi; Cell Movement; Cilia; Disease Models, Animal; Environmental Exposur | 1973 |
73 other studies available for guaifenesin and Hyperplasia
| Article | Year |
|---|---|
Staging of chronic hyperplastic rhinosinusitis: treatment strategies.
Topics: Beclomethasone; Cefuroxime; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Ethmoid | 1995 |
Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
Topics: Alveolar Epithelial Cells; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody-Dependent | 2021 |
Juvenile arsenic exposure aggravates goblet cell hyperplasia and airway mucus secretion in ovalbumin-sensitized mice.
Topics: Animals; Arsenic; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Drinking | 2022 |
ILC2s mediate systemic innate protection by priming mucus production at distal mucosal sites.
Topics: Animals; Cross Protection; Goblet Cells; Hyperplasia; Immunity, Innate; Interleukin-13; Intestinal M | 2019 |
Iloprost inhibits acute allergic nasal inflammation by GATA3 -ILC2 pathway in mice.
Topics: Animals; Disease Models, Animal; Female; GATA3 Transcription Factor; Goblet Cells; Hyperplasia; Ilop | 2020 |
The cecal mucus sign underlying appendiceal sessile serrated polyp/adenoma without dysplasia.
Topics: Adenoma; Colonic Polyps; Colorectal Neoplasms; Humans; Hyperplasia; Mucus | 2020 |
Amelioration of Cigarette Smoke-Induced Mucus Hypersecretion and Viscosity by
Topics: Animals; Cigarette Smoking; Dendrobium; Epithelial Cells; ErbB Receptors; Goblet Cells; Humans; Hype | 2020 |
A Small Molecule BH3-mimetic Suppresses Cigarette Smoke-Induced Mucous Expression in Airway Epithelial Cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cigarette Smoking; Epithelial Cells; Genes, erbB- | 2018 |
Effects of mucus thickness and goblet cell hyperplasia on microdosimetric quantities characterizing the bronchial epithelium upon radon exposure.
Topics: Bronchi; Epithelium; Goblet Cells; Hyperplasia; Mucus; Radiometry; Radon | 2018 |
Pulmonary Neuroendocrine Cells Secrete γ-Aminobutyric Acid to Induce Goblet Cell Hyperplasia in Primate Models.
Topics: Acute Lung Injury; Animals; Asthma; Bronchi; Disease Models, Animal; Epithelial Cells; gamma-Aminobu | 2019 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats.
Topics: Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Epithelial Cells; ErbB Receptors; Goblet Cells; Hy | 2013 |
Mucoactive effects of naringin in lipopolysaccharide-induced acute lung injury mice and beagle dogs.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Dogs; Elasticity; Female; Flavanones; Gobl | 2014 |
Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Disease Models, Animal; Eosino | 2015 |
Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma.
Topics: Airway Remodeling; Animals; Asthma; Blotting, Western; Bronchi; Bronchoalveolar Lavage Fluid; Diseas | 2015 |
Kaempferol Inhibits Endoplasmic Reticulum Stress-Associated Mucus Hypersecretion in Airway Epithelial Cells And Ovalbumin-Sensitized Mice.
Topics: Animals; Cell Line; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucle | 2015 |
Effect of P2X4R on airway inflammation and airway remodeling in allergic airway challenge in mice.
Topics: Actins; Airway Remodeling; Animals; Bronchi; Bronchoalveolar Lavage Fluid; Cell Count; Collagen; Fem | 2016 |
Ablation of Glutaredoxin-1 Modulates House Dust Mite-Induced Allergic Airways Disease in Mice.
Topics: Animals; Cytokines; Glutaredoxins; Glutathione; Hyperplasia; Hypersensitivity; Immunoglobulin E; Imm | 2016 |
Association of increased tracheal mucus accumulation with poor willingness to perform in show-jumpers and dressage horses.
Topics: Animals; Endoscopy; Female; Horse Diseases; Horses; Hyperplasia; Laryngeal Diseases; Lymphoid Tissue | 2009 |
CD4+ T-cell-dependent goblet cell proliferation and expulsion of Gymnophalloides seoi from the intestine of C57BL/6 mice.
Topics: Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes; Cell Proliferation; Disease Susceptibility; | 2009 |
Colitis cystica profunda presenting with a mucus pool within the stalk of a pedunculated colon polyp.
Topics: Adult; Colonic Diseases; Colonic Polyps; Colonoscopy; Cysts; Dilatation, Pathologic; Electrosurgery; | 2010 |
Glycyrrhizin attenuates mucus production by inhibition of MUC5AC mRNA expression in vivo and in vitro.
Topics: Animals; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regula | 2010 |
Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation.
Topics: Animals; Cytokines; Dendritic Cells; Flow Cytometry; Goblet Cells; Hyperplasia; Interleukin-17; Inte | 2010 |
Requirement of the epithelium-specific Ets transcription factor Spdef for mucous gland cell function in the gastric antrum.
Topics: Animals; Exocrine Glands; Gene Expression Regulation; Homeostasis; Hyperplasia; Mice; Mice, Knockout | 2010 |
Cigarette smoke suppresses Bik to cause epithelial cell hyperplasia and mucous cell metaplasia.
Topics: Animals; Blotting, Western; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Epithelial | 2011 |
Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.
Topics: Bronchi; Cell Differentiation; Clarithromycin; Enzyme Inhibitors; ErbB Receptors; Flavonoids; Goblet | 2011 |
Pseudomonas aeruginosa pyocyanin causes airway goblet cell hyperplasia and metaplasia and mucus hypersecretion by inactivating the transcriptional factor FoxA2.
Topics: Animals; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Goblet Cells; Hepatocyte Nuclear Factor | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An | 2012 |
In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo.
Topics: Apoptosis; Bronchi; Cell Differentiation; Chemokines; Child; Cilia; Cytopathogenic Effect, Viral; Ep | 2012 |
Role of nicotinic receptors and acetylcholine in mucous cell metaplasia, hyperplasia, and airway mucus formation in vitro and in vivo.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Bronchi; Epithelial Cells; Humans; Hyperplas | 2012 |
Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2/STAT6 pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Epithelial Cells; Gene Expression Regulation; Goblet | 2012 |
Sialendoscopic findings in patients with obstructive sialadenitis: long-term experience.
Topics: Adolescent; Adult; Aged; Constriction, Pathologic; Endoscopes; Endoscopy; Female; Follow-Up Studies; | 2013 |
Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Count; Chemokine CCL11; Chemokines, CC; Dexamethasone; E | 2003 |
Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia.
Topics: Biomarkers; Bronchi; Cell Differentiation; Cell Division; Cells, Cultured; Cilia; Epithelial Cells; | 2003 |
Expression of epidermal growth factor receptor and its ligands in chronic sinusitis.
Topics: Adult; Case-Control Studies; Chronic Disease; Epidermal Growth Factor; ErbB Receptors; Female; Goble | 2003 |
Utilization of knockout mice to examine the potential role of gastric histamine H2-receptors in Menetrier's disease.
Topics: Animals; Body Weight; Gastric Mucosa; Gastrins; Hydrogen-Ion Concentration; Hyperplasia; Hypoprotein | 2003 |
Complex role of the IL-4 receptor alpha in a murine model of airway inflammation: expression of the IL-4 receptor alpha on nonlymphoid cells of bone marrow origin contributes to severity of inflammation.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Bronchoalveolar Lavage Fluid; Disease Model | 2004 |
Effect of MMP/ADAM inhibitors on goblet cell hyperplasia in cultured human bronchial epithelial cells.
Topics: Bronchi; Cell Differentiation; Cells, Cultured; Dipeptides; Enzyme Inhibitors; Epithelial Cells; Erb | 2004 |
Superantigen hypothesis for the early development of chronic hyperplastic sinusitis with massive nasal polyposis.
Topics: Bacterial Toxins; Chronic Disease; Enterotoxins; Eosinophilia; Humans; Hyperplasia; Lymphocytes; Muc | 2005 |
Niflumic acid suppresses interleukin-13-induced asthma phenotypes.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Chloride Channels; Eosinophils; Goblet Cells; Hyperpl | 2006 |
Gob-5 contributes to goblet cell hyperplasia and modulates pulmonary tissue inflammation.
Topics: Airway Resistance; Animals; Antigens; Bronchoalveolar Lavage Fluid; Chemokines; Chloride Channels; D | 2006 |
The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
Topics: Acetates; Airway Obstruction; Animals; Anti-Asthmatic Agents; Asthma; Collagen; Cyclopropanes; Cyste | 2006 |
Effect of tracheal mucus and tracheal cytology on racing performance in Thoroughbred racehorses.
Topics: Age Factors; Analysis of Variance; Animals; Cough; Endoscopy; Female; Horse Diseases; Horses; Hyperp | 2006 |
A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Biological Availability; Bronchitis; Bronchoalveolar | 2007 |
Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Cells, Cultured; Epithelium; Gene Expression Regulation; | 2008 |
Characterization of glycoconjugates of human gastrointestinal mucosa by lectins. I. Histochemical distribution of lectin binding sites in normal alimentary tract as well as in benign and malignant gastric neoplasms.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Binding Sites; Gastric Mucosa; Glycoproteins; Histocytoche | 1984 |
Taenia taeniaeformis: increased cell growth and neutral mucus production in the gastric mucosa of the rat with a larval infection.
Topics: Animals; Cell Division; Cytoplasmic Granules; Female; Gastric Mucosa; Hexosamines; Hyperplasia; Larv | 1984 |
Quantitative study of bronchial mucous gland enlargement.
Topics: Bronchi; Bronchitis; Cell Count; Exocrine Glands; Humans; Hyperplasia; Male; Mucus | 1980 |
Hyperplastic effects of aerosolized sodium metabisulfite on rat airway mucus-secretory epithelial cells.
Topics: Aerosols; Animals; Disease Models, Animal; Epithelium; Glycoproteins; Hyperplasia; Hypertrophy; Lung | 1994 |
Effect of inhaled endotoxin on intraepithelial mucosubstances in F344 rat nasal and tracheobronchial airways.
Topics: Animals; Bronchi; Endotoxins; Hyperplasia; Male; Mucous Membrane; Mucus; Nasal Mucosa; Nose; Rats; R | 1994 |
Morphometric analysis of airways in Sjögren's syndrome.
Topics: Adult; Aged; Bronchi; Bronchitis; Chronic Disease; Exocrine Glands; Female; Humans; Hyperplasia; Mal | 1993 |
The role of 16,16-dimethyl prostaglandin E2 on the intrahepatic biliary branches in dogs.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Bacteroides Infections; Bile Ducts, Intrahepatic; Cholestas | 1993 |
Hypertrophic and metaplastic changes of goblet cells in rat nasal epithelium induced by endotoxin.
Topics: Animals; Endotoxins; Epithelium; Hyperplasia; Hypertrophy; Metaplasia; Mucus; Nasal Mucosa; Pancreat | 1996 |
Detection of colorectal neoplasia with peanut-agglutinin (PNA)-reactive carbohydrate structures in rectal mucus.
Topics: Adenoma; Adolescent; Adult; Child; Child, Preschool; Colitis, Ulcerative; Collodion; Colonic Polyps; | 1997 |
[Appendiceal mucocele disclosed by a psoas tumor. Apropos of a case].
Topics: Aged; Appendix; Cecal Diseases; Contrast Media; Diagnosis, Differential; Echinococcosis; Hemorrhage; | 1998 |
Bcl-2 in LPS- and allergen-induced hyperplastic mucous cells in airway epithelia of Brown Norway rats.
Topics: Aerosols; Allergens; Animals; Apoptosis; Eosinophils; Hyperplasia; Lipopolysaccharides; Male; Mucous | 2000 |
Adenomatoid hyperplasia of the palate mimicking clinically as a salivary gland tumor.
Topics: Adenoma, Pleomorphic; Adult; Case-Control Studies; Cell Division; Diagnosis, Differential; Follow-Up | 2001 |
The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Count; Chemokine CCL11; Chemokines, CC; Eosinophilia; Go | 2002 |
Relation of pancreatic duct hyperplasia to carcinoma.
Topics: Adolescent; Adult; Age Factors; Aged; Cell Transformation, Neoplastic; Child; Child, Preschool; Epit | 1979 |
Mucous secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and histochemical study.
Topics: Animals; Carcinoma in Situ; Cecum; Colon; Colonic Neoplasms; Dimethylhydrazines; Female; Hyperplasia | 1975 |
Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack.
Topics: Epithelium; Exocrine Glands; Female; Histocytological Preparation Techniques; Humans; Hyperplasia; L | 1992 |
Diagnosing the Muir-Torre syndrome.
Topics: Exocrine Glands; Humans; Hyperplasia; Keratoacanthoma; Mucus; Neoplasms, Multiple Primary; Odontogen | 1992 |
Goblet cell density in nasal polyps.
Topics: Basement Membrane; Cell Count; Epithelium; Humans; Hyperplasia; Mucus; Nasal Mucosa; Nasal Polyps; S | 1990 |
Chronic inflammation is associated with an increased proportion of goblet cells recovered by bronchial lavage.
Topics: Airway Obstruction; Bronchi; Bronchitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cell Count; Chr | 1991 |
Laryngeal morphology in sudden unexpected death in infants.
Topics: Exocrine Glands; Female; Humans; Hyperplasia; Infant; Infant, Newborn; Larynx; Male; Mucus; Posture; | 1991 |
Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia.
Topics: Acetylcysteine; Animals; Bronchi; Germ-Free Life; Hyperplasia; Male; Mucus; Nicotiana; Plants, Toxic | 1985 |
Carcinogenic effect of N-nitrosohexamethylenimine in Syrian golden hamsters.
Topics: Adenocarcinoma; Animals; Azepines; Carcinogens; Carcinoma, Squamous Cell; Cricetinae; Epithelium; Hy | 1973 |
Experimental bronchitis in lambs exposed to cigarette smoke.
Topics: Animals; Body Weight; Bronchi; Bronchitis; Cell Count; Environmental Exposure; Female; Hyperplasia; | 1973 |
[Exposure of rat to sulfurous anhydride. Bronchopulmonary effects as a function of time].
Topics: Animals; Bronchi; Carbon Radioisotopes; Cell Division; Hyperplasia; Lung; Lysine; Mucous Membrane; M | 1973 |
Experimental chronic bronchitis. Pathology in the dog.
Topics: Air; Animals; Bronchi; Bronchitis; Chronic Disease; Cilia; Disease Models, Animal; Dogs; Environment | 1974 |
Cheilitis glandularis.
Topics: Adult; Carcinoma, Squamous Cell; Cheilitis; Child; Child, Preschool; Dilatation; Exocrine Glands; Fe | 1971 |
Mucus production in gallstone formation--autoradiographs using tritiated galactose.
Topics: Animals; Autoradiography; Cholelithiasis; Galactose; Gallbladder; Glycoproteins; Hyperplasia; Mice; | 1971 |
Histochemical study of the mucosubstances in the canine stomach. 3. The effects of corticosteroids.
Topics: Administration, Oral; Animals; Autoradiography; Dogs; Gastric Mucosa; Gastritis; Histocytochemistry; | 1970 |
Mucus-secreting adenomatous polyp at the site of ureterosigmoidostomy. A case report and review of the literature.
Topics: Adenoma; Colon, Sigmoid; Colonic Neoplasms; Humans; Hyperplasia; Intestinal Polyps; Male; Middle Age | 1968 |